Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleclumab in Japanese patients with advanced solid malignancies
NCT03736473Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Primary completion
- Jun 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oleclumab in solid tumor (advanced stage), sponsored by AstraZeneca. Primary endpoint: Adverse Events (AEs). Started Nov 2018; status: completed.
02
Drugs
oleclumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03736473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736473.